Azafaros has raised €132 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead clinical-stage asset, AZ-3102, into two Phase 3 trials for the treatment of rare lysosomal storage disorders: GM1 and GM2 gangliosidosis.
This significant milestone marks one of the largest private biotech financings in Europe so far in 2025. The round was led by Forbion Growth and included new investors such as Sofinnova Partners, as well as strategic investor Sarepta Therapeutics, alongside existing investors.
With this financing, Azafaros is poised to accelerate late-stage development of innovative therapies that target multiple neurological symptoms of rare genetic diseases, bringing new hope to patients and families affected by these devastating conditions.
Read more here
December 8, 2025, The share of female professors is increasing, but the growth remains limited. With 34.2%, Leiden University ranks in the national top three, according to the...
Leiden, December 6, 2025, 12:15 PM – by Robbert Beurse - Every day, around 70,000 people in the Netherlands experience a migraine attack. The condition ranks among the five most...
The meteorological winter has begun, and with it, the flu season. Yet there is hope: the Leiden-based biotech company Leyden Labs is working on a promising innovation that could...